The alkylation of AIM2 by itaconate mediates macrophage PANoptosis during sepsis.

Summary

High itaconate levels covalently alkylate AIM2 at C113, stabilizing it to promote ASC oligomerization, PANoptosome assembly, and macrophage PANoptosis; the C113A mutation abrogates these effects. In vivo data confirm this itaconate–AIM2 axis exacerbates systemic sepsis, nominating AIM2 modification as a therapeutic target.

Key Findings

• Itaconate covalently alkylates AIM2 at cysteine 113, stabilizing AIM2 and inducing conformational activation.
• AIM2 activation drives ASC oligomerization, PANoptosome assembly, and macrophage PANoptosis.
• The AIM2 C113A mutation abolishes itaconate-induced AIM2 stabilization and PANoptosis in vitro.
• In vivo models demonstrate that the itaconate–AIM2 axis contributes to systemic sepsis pathogenesis.

Clinical Implications

While preclinical, targeting itaconate–AIM2 interactions or downstream PANoptosis offers a new therapeutic avenue to preserve macrophages and blunt hyperinflammation in severe sepsis.

Limitations

• Translational relevance requires human validation; pathophysiological itaconate levels and cell-specific effects in patients are not defined.
• Therapeutic modulation feasibility (on-target selectivity and safety) remains untested.

Future Directions

Define itaconate levels and AIM2 modifications in human sepsis; evaluate pharmacologic inhibitors of AIM2 activation or PANoptosis; explore cell-type specificity and timing for intervention.